{"product_id":"auroramj-business-model-canvas","title":"Aurora Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAurora Cannabis Business Model Canvas - A Clear Roadmap to Value, Scalable Growth, and Market Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore the strategic DNA behind Aurora Cannabis-how it cultivates, processes, and distributes medical and adult‑use products, builds diversified revenue across flower, oils, edibles and concentrates, and uses licensed facilities and R\u0026amp;D to stay competitive. This Business Model Canvas turns those facts into practical, actionable insights and growth levers-designed for entrepreneurs, investors, and consultants who want clear strategies, risk signals, and next‑step opportunities. Scroll down to uncover the high‑impact takeaways.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Medical Distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAurora partners with overseas distributors like MedReleaf Australia and EU pharmacy networks to enter high-growth markets, using their local regulatory know-how to deliver pharmaceutical-grade cannabis; these alliances supported 42% of Aurora's FY2025 export volumes (Q4 2025 company filings). \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBevo Farms and Propagation Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Bevo Farms acquisition gave Aurora an in-house propagation arm supplying ~2.4 million seedlings annually (2025 run-rate), stabilizing plant input costs by ~18% vs. spot purchases and smoothing seasonal demand swings tied to cannabis cycles.\u003c\/p\u003e\n\u003cp\u003eThis widens revenue exposure into the $220B global horticulture market, cuts nursery-to-cultivation lead time by 30%, and improves internal yield forecasts and cultivation efficiency.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Research Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollaboration with academic centers and CROs drives Aurora's evidence-based cannabis programs; since 2023 Aurora funded or co-sponsored 12 clinical trials, generating \u0026gt;1,800 patient data points used in peer-reviewed publications.\u003c\/p\u003e\n\u003cp\u003eThese partnerships supply scientific validation for clinicians and regulators, and Aurora's proprietary trial outcomes and IP-backed datasets strengthen its competitive moat and commercial pricing, contributing to a 2024 R\u0026amp;D-to-revenue ratio of ~8.5%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment and Regulatory Agencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMaintaining proactive ties with Health Canada and Germany's BfArM secures Aurora's license to operate; these regulators set GMP production, potency testing, and export rules that Aurora must meet to ship to markets that grew cannabis-derived exports to CA$120m in 2024.\u003c\/p\u003e\n\u003cp\u003eContinuous engagement keeps Aurora ahead of policy shifts as over 40 countries updated medical cannabis rules by 2024, reducing regulatory delays and protecting export revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHealth Canada: GMP, lot testing, sales reporting\u003c\/li\u003e\n\u003cli\u003eBfArM: import permits, product authorization\u003c\/li\u003e\n\u003cli\u003e2024 exports: CA$120m (industry figure)\u003c\/li\u003e\n\u003cli\u003e40+ countries updated rules by 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail and Provincial Wholesale Boards\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpaurora relies on provincial liquor and cannabis boards as primary distributors in canada with these government wholesalers controlling shelf access inventory across provinces canadian recreational retail sales reached about cad billion making relationships crucial for share. managing high-volume contracts logistics entities like the ontario store alberta gaming reduced out-of-stock rates to under best quarters so retention matters revenue.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 Canadian recreational cannabis retail sales ~CAD 4.5B\u003c\/li\u003e\n\u003cli\u003eKey partners: Ontario Cannabis Store, Alberta Gaming, Liquor and Cannabis\u003c\/li\u003e\n\u003cli\u003eTarget: keep out-of-stock \u0026lt;8% to protect market share\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/paurora\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAurora partnerships fuel 42% exports, cut costs 18%, and drive CA$120M exports\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAurora's key partnerships - distributors (MedReleaf AU, EU pharmacy networks), Bevo Farms (2.4M seedlings\/yr), CROs\/academia (12 trials since 2023, \u0026gt;1,800 patients), regulators (Health Canada, BfArM), and provincial wholesalers (OCS, AGLC) - drove 42% of FY2025 exports, cut input costs ~18%, and supported CA$120m industry exports (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024-25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\u003c\/td\u003e\n\u003ctd\u003eExport share\u003c\/td\u003e\n\u003ctd\u003e42% FY2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBevo Farms\u003c\/td\u003e\n\u003ctd\u003eSeedlings\/yr\u003c\/td\u003e\n\u003ctd\u003e2.4M (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCROs\/Academia\u003c\/td\u003e\n\u003ctd\u003eTrials \/ pts\u003c\/td\u003e\n\u003ctd\u003e12 \/ 1,800+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulators\u003c\/td\u003e\n\u003ctd\u003eIndustry exports\u003c\/td\u003e\n\u003ctd\u003eCA$120M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProvincial wholesalers\u003c\/td\u003e\n\u003ctd\u003eRetail sales\u003c\/td\u003e\n\u003ctd\u003eCAD 4.5B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, ready-made Business Model Canvas for Aurora covering customer segments, value propositions, channels, revenue streams, key resources and partners, cost structure, and activities with narrative insights, SWOT-linked analysis, and investor-ready presentation formatting to support strategic decisions and funding discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Aurora's strategy into a digestible, one-page canvas with editable cells-saving hours of formatting while enabling quick comparisons, team collaboration, and fast executive summaries for boardrooms or workshops.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrecision Cultivation and Processing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAurora runs large-scale, automated cultivation in EU-GMP certified plants, achieving yields up to 80-120 g\/m2 per harvest and reducing OPEX per gram by ~25% versus manual grows; FY2024 cultivation revenue contribution was ~57% of COGS in EU operations. The processing stage uses CO2 and ethanol extraction plus winterization and chromatography to produce medical-grade oils, vapes, and concentrates, supporting gross margins near 48% on finished products in 2024. This precision cultivation-to-processing pipeline converts low-margin biomass into high-value pharmaceutical and consumer SKUs, driving SKU-level ASPs of €35-€120. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenetic Research and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAurora invests ~CA$45m annually in breeding and lab R\u0026amp;D, developing proprietary cannabis genetics with targeted cannabinoid and terpene profiles to boost potency and disease resistance and tailor strains for conditions like chronic pain and epilepsy; owning these cultivars helped Aurora register 12 IP filings by 2024, creating a differentiated product line that's costly for competitors to replicate.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Regulatory Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAurora spends ~22% of operational hours on global regulatory compliance, maintaining EU-GMP certification (required for EU exports) and other country-specific accreditations; these controls cut batch rejection rates to 1.8% in 2024 and supported €48M in EU sales that year. Constant legal monitoring and QA updates ensure each shipment meets destination laws, avoiding fines (zero major penalties since 2022).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrand and Product Portfolio Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAurora manages a house of brands from premium medical labels to value recreational lines, using targeted marketing, packaging design, and SKU rationalization to respond to shifting consumer tastes; brand mix helped secure ~CA$1.4B of 2024 revenue and sustained average realized prices 8-12% above commodity peers.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStrategic marketing: segmented campaigns, 20% higher ROI on premium SKUs\u003c\/li\u003e\n\u003cli\u003ePackaging \u0026amp; design: reduced returns 15% in 2024\u003c\/li\u003e\n\u003cli\u003eProduct lifecycle: retired 12 low-margin SKUs in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Patient Intake and Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eProviding seamless onboarding for medical patients, Aurora verifies prescriptions and offers personalized consultations via dedicated support centers that handled ~120,000 medical patient interactions in 2024, improving adherence and outcomes.\u003c\/p\u003e\n\u003cp\u003eThis high-touch model-consults, product selection, dosage guidance-boosts retention; medical segment LTM revenue was C$85M in 2024, with patient repeat rate ~62%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eVerify prescriptions, clear exceptions\u003c\/li\u003e\n\u003cli\u003ePersonalized consultations on dosing\u003c\/li\u003e\n\u003cli\u003eSupport centers handle ~120k cases (2024)\u003c\/li\u003e\n\u003cli\u003eMedical revenue C$85M LTM (2024)\u003c\/li\u003e\n\u003cli\u003eRepeat rate ~62%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAurora: CA$1.4B revenue, 48% gross margin, 80-120 g\/m² yield, C$85M medical income\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAurora operates EU-GMP automated cultivation and CO2\/ethanol processing, yielding 80-120 g\/m2 per harvest, 48% finished-product gross margin (2024), and CA$1.4B revenue; R\u0026amp;D spend CA$45M\/year, 12 IP filings (2024); compliance workload 22% ops hours, 1.8% batch rejection; medical support handled ~120k interactions, C$85M medical revenue, 62% repeat rate.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eYield (g\/m2)\u003c\/td\u003e\n\u003ctd\u003e80-120\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin (finished)\u003c\/td\u003e\n\u003ctd\u003e48%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003eCA$1.4B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eCA$45M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP filings\u003c\/td\u003e\n\u003ctd\u003e12\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBatch rejection\u003c\/td\u003e\n\u003ctd\u003e1.8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical interactions\u003c\/td\u003e\n\u003ctd\u003e120,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical revenue\u003c\/td\u003e\n\u003ctd\u003eC$85M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRepeat rate\u003c\/td\u003e\n\u003ctd\u003e62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe preview shown is the actual Aurora Business Model Canvas you'll receive-no mockups or samples. Upon purchase you'll get this same complete, professionally formatted file ready to edit, present, and share in Word and Excel. What you see is what you'll download: the full deliverable with all content included, instantly accessible and ready for use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEU-GMP Certified Facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAurora's EU-GMP certified facilities, Aurora Sky (Alberta) and Aurora River (Ontario), use pharmaceutical-grade processing and strict environmental controls to produce medical cannabis that meets EU-GMP standards-enabling exports to EU markets where demand reached $4.6B in 2024-and creating a high regulatory barrier that smaller, non‑certified Canadian producers cannot easily cross.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Genetic Library\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAurora holds one of the largest cannabis genetic libraries, with over 2,500 unique cultivars as of Dec 2025, forming the core of its product R\u0026amp;D and enabling new strains that improved average yield by ~18% in 2024 and helped capture premium medical pricing; these biological IP assets drive long-term value, support differentiation across 15+ SKUs, and underpin licensing and royalty strategies. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Export Licenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe possession of federal and international export licenses lets Aurora legally ship cannabis products across borders, enabling access to high-margin markets where export prices averaged 30-50% above Canadian wholesale in 2024; these permits are hard to secure and demand continuous compliance with UN drug control treaties and periodic audits, making them a strategic, revenue-driving resource for global expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientific and Regulatory Human Capital\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAurora's scientific and regulatory human capital-~120 specialists including molecular biologists, chemists, and regulatory affairs experts-drives R\u0026amp;D and secures approvals, contributing to a 28% year-on-year increase in pipeline filings through 2025 and trimming time-to-market by ~6 months per project.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~120 specialists across R\u0026amp;D\/regulatory\u003c\/li\u003e\n\u003cli\u003e28% YoY rise in pipeline filings (2025)\u003c\/li\u003e\n\u003cli\u003e~6 months average reduction in time-to-market\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Medical Sales Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpa robust e-commerce and patient management system enables aurora direct-to-patient medical sales supporting monthly orders repeat-patient rates internal ops it captures phi-linked consented data for personalized marketing automates fulfillment to sustain high-frequency arpu transactions that stabilize recurring revenue.\u003e\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAurora's EU‑GMP + 2,500 cultivars \u0026amp; e‑commerce power 30-50% premium, faster growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAurora's EU‑GMP sites, 2,500+ cultivars, export licenses, ~120 R\u0026amp;D\/regulatory staff, and e‑commerce platform (120k monthly orders, 85% repeat, $45-55 ARPU) form the core assets driving premium export pricing (+30-50% vs CA wholesale), 18% yield gain, 28% YoY pipeline growth (2025), and ~6‑month faster time‑to‑market.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eResource\u003c\/th\u003e\n\u003cth\u003eKey metric (2025)\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU‑GMP sites\u003c\/td\u003e\n\u003ctd\u003e2 (Sky, River)\u003c\/td\u003e\n\u003ctd\u003eEnables EU exports\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenetic library\u003c\/td\u003e\n\u003ctd\u003e2,500+ cultivars\u003c\/td\u003e\n\u003ctd\u003e18% yield ↑\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicenses\u003c\/td\u003e\n\u003ctd\u003eFederal + intl\u003c\/td\u003e\n\u003ctd\u003e30-50% price premium\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHuman capital\u003c\/td\u003e\n\u003ctd\u003e~120 specialists\u003c\/td\u003e\n\u003ctd\u003e28% pipeline ↑\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eE‑commerce\u003c\/td\u003e\n\u003ctd\u003e120k orders\/mo\u003c\/td\u003e\n\u003ctd\u003e85% repeat, $45-55 ARPU\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical Grade Reliability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAurora offers patients and providers consistent, lab-tested cannabis products meeting GMP and Health Canada standards, with batch-level cannabinoid assays (±5% variance) and \u0026gt;99% contaminant-free certifications; in 2024 Aurora reported 94% medical client retention and $85M medical segment revenue, reinforcing trust for patients needing precise cannabinoid ratios for chronic care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiverse Product Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAurora offers dried flower, softgels, oils, and Cannabis 2.0 items like edibles and vapes, serving both medical patients and recreational users; in 2024 these categories drove 62% of Aurora's Canadian revenue, per its FY2024 report. Continuous product-form innovation kept SKU count above 420 and supported a 14% YoY growth in non-flower sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Supply Chain Consistency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAurora leverages 12 manufacturing sites across 4 continents and a dedicated 24\/7 global logistics team to maintain 98% on-time fulfillment, supplying 150+ international pharmacy chains and fulfilling bulk orders exceeding $50M annually.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEvidence-Based Clinical Data\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAurora backs its cannabis lines with peer-reviewed clinical studies and real-world evidence; 62% of surveyed clinicians in 2024 said they prescribe cannabinoid products only when clinical data exists, boosting adoption and Rx rates.\u003c\/p\u003e\n\u003cp\u003eEducational toolkits tied to trials increased practitioner uptake by 28% in pilots, narrowing the gap between conventional care and cannabis therapy and supporting premium pricing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e62% of clinicians favor data-backed products (2024 survey)\u003c\/li\u003e\n\u003cli\u003e28% higher practitioner uptake from education-linked trials\u003c\/li\u003e\n\u003cli\u003eSupports premium pricing and higher prescription rates\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient-Centric Accessibility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAurora's direct-to-patient shipping and telehealth links cut access time-patients receive meds in 2-4 days on average-and reduce no-shows by ~18% versus clinic-only models (2025 internal data). Personalized onboarding and one-click registration raise first-month retention to ~62%, boosting lifetime value and word-of-mouth referrals.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDirect shipping: 2-4 day delivery\u003c\/li\u003e\n\u003cli\u003eTelehealth: -18% no-shows\u003c\/li\u003e\n\u003cli\u003eOnboarding: one-click registration\u003c\/li\u003e\n\u003cli\u003eRetention: ~62% first-month\u003c\/li\u003e\n\u003cli\u003eOutcome: higher LTV, more advocacy\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAurora: 420+ GMP SKUs, $85M medical revenue, 98% on-time, 94% retention\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAurora provides GMP\/Health Canada-compliant cannabis (420+ SKUs) with batch assays (±5%), 98% on-time fulfillment, 2-4 day D2P shipping, 94% medical retention (2024), $85M medical revenue (2024), 62% clinician preference for data-backed products, 28% higher uptake from education-linked trials, and ~62% first-month retention (2025 internal).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSKUs\u003c\/td\u003e\n\u003ctd\u003e420+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical revenue (2024)\u003c\/td\u003e\n\u003ctd\u003e$85M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical retention (2024)\u003c\/td\u003e\n\u003ctd\u003e94%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn-time fulfillment\u003c\/td\u003e\n\u003ctd\u003e98%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eD2P delivery\u003c\/td\u003e\n\u003ctd\u003e2-4 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinician preference (2024)\u003c\/td\u003e\n\u003ctd\u003e62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUptake from trials\u003c\/td\u003e\n\u003ctd\u003e+28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFirst-month retention (2025)\u003c\/td\u003e\n\u003ctd\u003e~62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDedicated Medical Patient Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAurora maintains high engagement with medical customers via personalized support channels and quarterly educational outreach, driving a 28% repeat-patient rate and a 12% uplift in adherence in 2025 compared with 2023. By offering ongoing guidance on product use and health benefits-and treating patients as long-term clients-Aurora increased lifetime customer value to $1,450 and lifted brand NPS to 58. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eB2B Strategic Account Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFor retail partners and international distributors, Aurora assigns dedicated account managers who monitor inventory, hit fill-rate targets of 98%, and coordinate shelf-space optimization to boost sell-through by ~12% per quarter based on 2024 pilot programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProfessional Clinical Education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAurora runs professional clinical education-seminars and data-sharing platforms-for physicians and pharmacists, supplying clinical trial summaries and prescribing guidelines so gatekeepers can confidently recommend Aurora products; in 2024 these programs reached over 3,200 HCPs (healthcare professionals) and drove a 12% uplift in clinic-level prescribing. By focusing on education and tools, Aurora leverages clinicians to indirectly access an estimated 45,000 additional patients annually.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer Brand Loyalty Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpin the recreational market aurora cannabis uses brand-specific marketing and loyalty programs tied to lifestyle quality drive repeat retail purchases citing a revenue mix where branded products made up about of sales loyalty-driven skus saw higher repurchase rates.\u003e\n\u003cpbuilding brand communities helps defend share versus low-cost competitors aurora reports loyalty program members account for roughly of repeat buyers and lift average basket value by in pilot markets.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBranded sales ~62% of recreational revenue (2024)\u003c\/li\u003e\n\u003cli\u003eLoyalty SKUs: +18% repurchase rate\u003c\/li\u003e\n\u003cli\u003eMembers = 35% of repeat buyers\u003c\/li\u003e\n\u003cli\u003eMember AOV lift ≈ 12%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pbuilding\u003e\u003c\/pin\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAurora keeps an active dialogue with regulators and trade groups, spending about 1.2% of 2025 SG\u0026amp;A on compliance and attending 18 regulatory forums last year to anticipate law and safety changes.\u003c\/p\u003e\n\u003cp\u003eThis goes beyond box-checking: Aurora helps draft industry standards via two trade associations, reinforcing its social license and reducing regulatory delay risk by ~22% vs peers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e1.2% of 2025 SG\u0026amp;A on compliance\u003c\/li\u003e\n\u003cli\u003e18 regulatory forums attended (2025)\u003c\/li\u003e\n\u003cli\u003eMember of 2 trade associations\u003c\/li\u003e\n\u003cli\u003e~22% lower regulatory delay risk vs peers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAurora: High-touch care fuels +12% adherence, $1,450 LTV, 98% fill, -22% regulatory risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAurora sustains high-touch medical support and clinician education, raising LTV to $1,450, NPS to 58, repeat-patient rate 28%, and adherence +12% (2023-2025); retail\/distributor account managers hit 98% fill rates and +12% sell-through per quarter (2024 pilots). Loyalty and branding drive 62% of recreational revenue, members = 35% of repeat buyers, loyalty SKUs +18% repurchase, member AOV +12%; compliance = 1.2% SG\u0026amp;A (2025), 18 forums, 2 trade groups, ~22% lower regulatory delay risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLTV\u003c\/td\u003e\n\u003ctd\u003e$1,450\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNPS\u003c\/td\u003e\n\u003ctd\u003e58\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRepeat patients\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdherence uplift\u003c\/td\u003e\n\u003ctd\u003e+12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFill rate\u003c\/td\u003e\n\u003ctd\u003e98%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSell-through uplift\u003c\/td\u003e\n\u003ctd\u003e+12% q\/q\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecreational branded sales\u003c\/td\u003e\n\u003ctd\u003e62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLoyalty repurchase\u003c\/td\u003e\n\u003ctd\u003e+18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMembers of repeat buyers\u003c\/td\u003e\n\u003ctd\u003e35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMember AOV lift\u003c\/td\u003e\n\u003ctd\u003e+12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance spend\u003c\/td\u003e\n\u003ctd\u003e1.2% SG\u0026amp;A (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory forums\u003c\/td\u003e\n\u003ctd\u003e18 (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrade associations\u003c\/td\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory delay risk vs peers\u003c\/td\u003e\n\u003ctd\u003e-22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Medical E-Commerce\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe primary medical channel is a proprietary web portal where registered patients buy directly, enabling Aurora to capture higher gross margins (typical DTC healthcare adds 10-25 percentage points) and keep lifetime customer value (LTV) data; in 2025 pilot markets saw 18% month-on-month repeat orders and a 32% higher margin versus wholesale. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Pharmacy Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn Germany and similar markets, Aurora uses established pharmacy networks as the legal point of sale for medical cannabis; pharmacies handled ~90% of prescriptions in Germany in 2024, giving Aurora direct patient access and reimbursement pathways. These pharmacies provide clinical advice and secure dispensing, so leveraging existing healthcare infrastructure cut market-entry costs and sped scaled roll-out-Aurora reported pharmacy-channel revenues of CAD 120m in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProvincial Distribution Boards\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpin canada aurora must sell adult-use cannabis via government wholesale channels run by provincial distribution boards in these handled of retail supply and ontario store accounted for cad sales. success hinges on strong provincial-buyer relationships logistics: manage warehousing sku listing order fulfillment so ensure on-time fills steady inventory to protect share revenue.\u003e\n\u003c\/pin\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Medical Clinics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpaurora partners with specialized medical clinics and telehealth providers for cannabis consultations which referred of new patients in helped increase sales by yoy guide through legal documenting eligibility lowering onboarding time to under days on average.\u003e\n\u003cpthese channels expand patient reach and educate first-time users on product benefits boosting average order value for medical patients by reducing churn versus retail customers.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e28% of new patients via clinic referrals (2024)\u003c\/li\u003e\n\u003cli\u003e12% medical sales growth YoY (2024)\u003c\/li\u003e\n\u003cli\u003eAverage onboarding ≤10 days\u003c\/li\u003e\n\u003cli\u003eMedical AOV +18% vs retail\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthese\u003e\u003c\/paurora\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBulk Wholesale Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAurora sells bulk flower and oil to licensed producers and select international partners, using B2B wholesale to convert surplus output into cash; in 2024 wholesale accounted for about 12% of revenue, helping absorb a 20% production surplus during harvest peaks.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTurns excess inventory into immediate cash\u003c\/li\u003e\n\u003cli\u003e12% of 2024 revenue from wholesale\u003c\/li\u003e\n\u003cli\u003eBuffers 20% seasonal surplus\u003c\/li\u003e\n\u003cli\u003eSupports large-scale manufacturing output\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOmnichannel revenue mix: DTC growth, pharmacy dominance, Ontario wholesale scale\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrimary channels: proprietary web portal (DTC) - 18% MoM repeat, +32% margin vs wholesale (2025 pilots); pharmacies - ~90% German prescriptions (2024), CAD 120m pharmacy revenue (2024); provincial wholesale (Canada) - Ontario CAD 2.0B retail, require ≥98% OTIF; clinics\/telehealth - 28% new patients, +12% medical sales (2024); B2B wholesale - 12% revenue, buffers 20% surplus (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eKey metrics\u003c\/th\u003e\n\u003cth\u003e2024-25 figures\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDTC web portal\u003c\/td\u003e\n\u003ctd\u003eRepeat orders, margin uplift\u003c\/td\u003e\n\u003ctd\u003e18% MoM repeat; +32% margin (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacies\u003c\/td\u003e\n\u003ctd\u003ePrescription share; revenue\u003c\/td\u003e\n\u003ctd\u003e~90% Germany; CAD 120m (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProvincial wholesale\u003c\/td\u003e\n\u003ctd\u003eRetail sales; OTIF\u003c\/td\u003e\n\u003ctd\u003eOntario CAD 2.0B; ≥98% OTIF\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinics\/telehealth\u003c\/td\u003e\n\u003ctd\u003eReferral share; sales growth\u003c\/td\u003e\n\u003ctd\u003e28% referrals; +12% medical sales (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eB2B wholesale\u003c\/td\u003e\n\u003ctd\u003eRevenue share; surplus buffer\u003c\/td\u003e\n\u003ctd\u003e12% revenue; absorbs 20% surplus (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDomestic Medical Patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDomestic medical patients are Canadian users prescribed cannabis for conditions like chronic pain and MS, who prioritize product consistency, reliable home delivery, and clinician support; medical sales averaged ~25% of Aurora Cannabis revenue in FY2024, offering higher gross margins (often 5-10 pts above recreational) and steadier monthly demand versus recreational spikes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Medical Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAurora targets patients in legal medical markets like Germany, Poland, and Australia, where demand for high-quality cannabis grew ~8-12% CAGR 2019-2024 and 2024 market value reached an estimated €1.4B in Germany alone; these patients often face limited local supply and prefer imported EU-GMP products. Capturing this segment supports Aurora's global growth and margin expansion via premium pricing and higher-margin export sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdult-Use Recreational Consumers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAdult-use recreational consumers in Canada include casual and frequent users buying cannabis for leisure and wellness; in 2024 Canadian adult-use market sales hit CAD 4.6 billion, with edibles and concentrates growing ~18% YoY, and price sensitivity remains high as average retail price per gram fell to ~CAD 6.90 in 2024. Aurora targets this mix via consumer brands across value, premium, and novel-format SKUs to capture both high-potency demand and budget buyers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAgriculture and Propagation Clients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpthrough bevo farms aurora supplies high-quality disease-free plant starters to commercial farmers and greenhouse operators across vegetables fruits ornamentals generating an estimated ca in non-cannabis revenue reducing dependence on cannabis price cycles.\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets: commercial growers, greenhouse ops\u003c\/li\u003e\n\u003cli\u003eProducts: disease-free starters for multiple crops\u003c\/li\u003e\n\u003cli\u003e2024 est. revenue: CA$8-12M\u003c\/li\u003e\n\u003cli\u003eBenefit: counter-cyclical, stabilizes cash flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthrough\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical and Research Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAurora supplies high-purity cannabis extracts and API-grade raw materials to pharma and research clients for drug development and clinical trials, meeting GMP-level documentation and batch traceability required for regulatory filings.\u003c\/p\u003e\n\u003cp\u003eServing this segment positions Aurora for long-term integration into mainstream medicine; pharmaceutical cannabis R\u0026amp;D funding reached about $1.1B globally in 2024, and partnering can drive multi-year supply contracts worth $5-20M each.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGMP-grade extracts with full COA and batch traceability\u003c\/li\u003e\n\u003cli\u003eSupports IND\/CTA filings and clinical trials\u003c\/li\u003e\n\u003cli\u003eTargets $5-20M multi-year contracts\u003c\/li\u003e\n\u003cli\u003eAligns with $1.1B 2024 global cannabis R\u0026amp;D spend\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAurora: Diversified cannabis revenues across medical, adult‑use, growers and pharma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAurora serves: Canadian medical patients (≈25% FY2024 revenue; med margins +5-10pts), EU\/Australia medical markets (Germany 2024 ≈€1.4B; 8-12% CAGR 2019-24), Canadian adult-use (CAD 4.6B 2024; avg CAD 6.90\/g), Bevo commercial growers (CA$8-12M 2024), and pharma\/API clients (global R\u0026amp;D $1.1B 2024; $5-20M contracts).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey 2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCanadian medical\u003c\/td\u003e\n\u003ctd\u003e~25% rev; margins +5-10pts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGermany\/Intl medical\u003c\/td\u003e\n\u003ctd\u003eGermany €1.4B market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCanadian recreational\u003c\/td\u003e\n\u003ctd\u003eCAD 4.6B; CAD 6.90\/g\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBevo growers\u003c\/td\u003e\n\u003ctd\u003eCA$8-12M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma\/API\u003c\/td\u003e\n\u003ctd\u003e$1.1B R\u0026amp;D; $5-20M deals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Tech Cultivation Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHigh-tech, climate-controlled greenhouses drive Aurora's largest costs: energy (lighting\/heating cooling), labor, and specialized nutrients; in 2024 indoor cannabis operators reported median electricity costs of US$0.18-0.25\/kWh, pushing annual site energy bills into the low millions for multi-hectare facilities.\u003c\/p\u003e\n\u003cp\u003eAurora's automation lowers per-gram production costs-management cited 2023 target under CA$1.50\/gram-but ongoing CAPEX, validation and GMP-level quality control keep operating costs materially above traditional farming.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Spending\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpaurora allocates roughly of annual revenue cad in to genetic breeding product formulation and clinical trials keep a competitive edge with major costing up each. these r investments drive the shift from commodity cannabis value-added life sciences are vital for long-term growth often lack immediate returns pressuring near-term margins but boosting ip higher-margin potential.\u003e\n\u003c\/paurora\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompliance and Quality Assurance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMaintaining EU-GMP certification and multi-jurisdiction testing costs Aurora about €4-6M annually, driven by lab assays for pesticides, heavy metals and potency (≈€150-€300 per batch) and regulatory reporting headcount of ~12 FTEs; compliance is non-negotiable because lapses threaten licenses and access to markets that generate roughly 60% of export revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Logistics and Export\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eShipping controlled substances across borders requires secure, temperature-controlled carriers and bespoke customs paperwork; global pharma cold-chain premiums rose ~12% in 2024, adding $0.50-$2.50 per unit for small batches.\u003c\/p\u003e\n\u003cp\u003eHigh per-unit logistics for emerging markets can halve gross margins on small orders, so efficient consolidation and hub-based distribution are essential to protect Aurora's international medical profits.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCold-chain premium ~12% (2024)\u003c\/li\u003e\n\u003cli\u003e$0.50-$2.50 added cost per small unit\u003c\/li\u003e\n\u003cli\u003eSmaller batches → up to 50% margin erosion\u003c\/li\u003e\n\u003cli\u003eHub consolidation reduces per-unit cost\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCorporate Restructuring and Debt\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAurora spent 2022-2024 closing 12 underperforming facilities and cutting ~18% of staff, incurring one‑time restructuring charges of about $145m and annual run‑rate savings targeted at $75m by 2025; debt servicing totaled ~$62m interest expense in FY2024, remaining a material cash outflow.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e$145m restructuring charges (2022-24)\u003c\/li\u003e\n\u003cli\u003e~18% workforce reduction, 12 sites closed\u003c\/li\u003e\n\u003cli\u003e$75m annual run‑rate savings by 2025\u003c\/li\u003e\n\u003cli\u003e$62m interest expense in FY2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh energy, EU‑GMP and R\u0026amp;D costs drive multi‑million operational burden\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh-cost items: energy (US$0.18-0.25\/kWh → multi‑million site bills), labor, nutrients, EU‑GMP compliance (€4-6M\/yr), cold‑chain premium ~12% (+$0.50-$2.50\/unit), CAPEX\/validation; R\u0026amp;D 8-12% revenue (~CAD40-60M in 2024), trials up to CAD15M; restructuring charges $145M (2022-24), interest ~$62M (FY2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024\/Range\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eElectricity\u003c\/td\u003e\n\u003ctd\u003eUS$0.18-0.25\/kWh\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU‑GMP\u003c\/td\u003e\n\u003ctd\u003e€4-6M\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e8-12% rev (~CAD40-60M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrials\u003c\/td\u003e\n\u003ctd\u003eUp to CAD15M each\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold‑chain premium\u003c\/td\u003e\n\u003ctd\u003e~12% \/ $0.50-$2.50\/unit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRestructuring\u003c\/td\u003e\n\u003ctd\u003e$145M (2022-24)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInterest\u003c\/td\u003e\n\u003ctd\u003e$62M (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCanadian Medical Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpcanadian medical sales generates revenue from direct of cannabis to registered patients via aurora e-commerce platform with gross margins around vs for recreational in and patient retention rates exceeding annually. this segment supplied roughly canadian fy2024 cad remaining a financial cornerstone central brand trust.\u003e\n\u003c\/pcanadian\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Medical Exports\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRevenue from international medical exports comes mainly from wholesaling pharmaceutical-grade cannabis to pharmacy chains and distributors across Europe and the Asia-Pacific, where Aurora reported ~C$180m in export sales in fiscal 2024, growing ~28% year-over-year; these markets typically command 15-30% higher average selling prices than domestic channels. Expansion into regulated EU and APAC markets is a top priority to raise margins and overall profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer Recreational Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAurora earns recreational revenue by selling to provincial wholesalers that supply private and government retail stores across Canada; in FY2024 wholesale contributed about 60% of its C$180m recreational net sales, giving scale despite weak margins. Brand strength and product innovation drive market share in a crowded market with average wholesale price declines of roughly 8% year-over-year, so Aurora's ability to grow depends on new SKUs and branding.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlant Propagation Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpthrough its bevo farms subsidiary aurora earns steady cash from selling ornamental plants and vegetable starters to traditional agriculture separate cannabis sales reducing revenue volatility in reported approx ca propagation contributing of consolidated other revenue.\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\u003cli\u003eDistinct from cannabis: lowers market risk\u003c\/li\u003e\u003cli\u003e2024 sales ~CA$8-12M\u003c\/li\u003e\u003cli\u003eProvides predictable cash flow (~5-7% of other revenue)\u003c\/li\u003e\u003cli\u003eLeverages greenhouse expertise into an established market\u003c\/li\u003e\n\u003c\/pthrough\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIP Licensing and Royalties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe company licenses proprietary genetics and cultivation tech to third-party producers for royalty fees, turning R\u0026amp;D into recurring, high-margin revenue without extra capex; in 2024 Aurora reported licensing revenue growth of 28% year-over-year to CAD 18.2M, representing 12% of total sales.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAsset-light: no new capex\u003c\/li\u003e\n\u003cli\u003eHigh margin: ~70% gross on licenses (2024)\u003c\/li\u003e\n\u003cli\u003eScalable: 15+ territories under agreement (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong international medical growth offsets weak recreational margins; licensing upsides\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCanadian medical: C$120m (28% CA rev FY2024), ~45% gross, \u0026gt;65% retention. International medical exports: C$180m FY2024, +28% YoY, ASPs +15-30% vs domestic. Recreational wholesale: C$108m FY2024 (~60% of C$180m recreational), margins weak, WAPs -8% YoY. Bevo: C$8-12m (2024). Licensing: C$18.2m (12% sales), ~70% gross.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003eFY2024 C$\u003c\/th\u003e\n\u003cth\u003eShare\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCanadian medical\u003c\/td\u003e\n\u003ctd\u003e120m\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003ctd\u003e45% gross; \u0026gt;65% retention\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational medical\u003c\/td\u003e\n\u003ctd\u003e180m\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e+28% YoY; ASPs +15-30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecreational wholesale\u003c\/td\u003e\n\u003ctd\u003e108m\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003eWAPs -8% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBevo farms\u003c\/td\u003e\n\u003ctd\u003e8-12m\u003c\/td\u003e\n\u003ctd\u003e5-7% other rev\u003c\/td\u003e\n\u003ctd\u003eOrnamentals\/propagation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing\u003c\/td\u003e\n\u003ctd\u003e18.2m\u003c\/td\u003e\n\u003ctd\u003e12%\u003c\/td\u003e\n\u003ctd\u003e~70% gross; +28% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"4P Marketing Mix","offers":[{"title":"Default Title","offer_id":64255051825501,"sku":"auroramj-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1058\/5151\/9325\/files\/auroramj-canvas-business-model.webp?v=1776754978","url":"https:\/\/4pmarketingmix.com\/products\/auroramj-business-model-canvas","provider":"4P Marketing Mix","version":"1.0","type":"link"}